Towards personalized medicine in antifungal treatment: combination of pharmacogenetics and pharmacokinetics

• Autores: Sara Blanco Dorado
• Directores de la Tesis: M.ª Jesús Lamas Díaz (dir. tes.), Manuel Campos Toimil (dir. tes.), Anxo Fernández Ferreiro (dir. tes.)
• Lectura: En la Universidade de Santiago de Compostela ( España ) en 2020
• Idioma: inglés
• Tribunal Calificador de la Tesis: Olga Delgado Sánchez (presid.), Arturo González Quintela (secret.), Fernando Gutiérrez Nicolás (voc.)
• Materias:
  • Ciencias de la vida
    • Fisiología humana
      • Metabolismo humano
  • Ciencias agrarias
    • Fitopatología
      • Hongos
  • Ciencias médicas
    • Farmacodinámica
      • Procesos metabólicos de los medicamentos
    • Farmacología
• Enlaces
  • Tesis en acceso abierto en: MINERVA
• Resumen

  • Voriconazole is an antifungal agent used in aspergillosis and in fluconazole-resistant Candida spp. infections. Voriconazol is mainly metabolized by cytochrome 2C19 wich is highly polymorphic. A significant portion of patients fail to achieve therapeutic drug concentrations, with a consequently increased risk of therapeutic failure. In this work, the use of voriconazole in the real life clinical setting was studied and a HPLC method for the pharmacokinetic determination of voriconazole was developed. In addition, the factors of voriconazole pharmacokinetic variability were evaluated demonstrating the importance of CYP2C19 pharmacogenetics and pharmacokinetic drug-drug interactions.